TSRO Overview
Upcoming Projects (TSRO)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (TSRO)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (TSRO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (TSRO)
-
Tesaro (TSRO) expects Phase 3 trial of Niraparib in Patients With HRD-Positive Advanced Ovarian Cancer to conclude in March 2018
Ticker: TSRO
Occurred on: Jul 15, 2019 -
Tesaro (TSRO) Plans to Report Phase 2 AVANOVA Data in 2H 2018 Evaluating Niraparib + Bevacizumab in Ovarian Cancer
Ticker: TSRO
Occurred on: Jun 04, 2019 -
Tesaro (TSRO) to Identify First Clinical Candidate with MD Anderson for I-O Platform in 1H 2017
Ticker: TSRO
Occurred on: Nov 09, 2018 -
Tesaro (TSRO) Plans to Report Phase 2 QUADRA Data in Q1 2018 Evaluating Niraparib in Ovarian Cancer
Ticker: TSRO
Occurred on: Apr 24, 2018 -
PDUFA date for Rolapitant - intravenous (IV) set to October 25, 2017
Ticker: TSRO
Occurred on: Oct 25, 2017 -
Tesaro (TSRO) to Initiate Phase 1 Trial in Mid-2017 Evaluating TSR-022 in Combination with an Anti-PD-1 mAb in Various Tumor Types
Ticker: TSRO
Occurred on: Aug 08, 2017 -
Tesaro (TSRO) Expects Launch of VARUBI IV in U.S in Mid-2017 for Chemotherapy-Induced Nausea and Vomiting
Ticker: TSRO
Occurred on: Aug 08, 2017 -
Tesaro (TSRO) plan for commercial launch in Europe of VARUBI IV in Q2 2017
Ticker: TSRO
Occurred on: Aug 08, 2017 -
Tesaro (TSRO) to Identify Dose and Schedule for TSR-022 in Various Tumor Types by Mid 2017
Ticker: TSRO
Occurred on: Aug 08, 2017 -
Tesaro (TSRO) to Determine Potential Registration Strategy for Niraparib + TSR-042 in Ovarian Cancer and Other Cancers in 2H 2017
Ticker: TSRO
Occurred on: Jun 03, 2017 -
Tesaro (TSRO) to Enroll Phase 3 PRIMA Trial Evaluating Niraparib in 1L Ovarian Cancer Throughout 2017
Ticker: TSRO
Occurred on: May 11, 2017 -
Tesaro (TSRO) to Submit Investigational New Drug Application (IND) for TSR-033 in 2Q 2017
Ticker: TSRO
Occurred on: May 01, 2017 -
Tesaro (TSRO) to Finalize Registration Strategy and Initiate Registration Program for TSR-042 in Various Tumor Types in 1H 2017
Ticker: TSRO
Occurred on: Apr 27, 2017 -
Tesaro (TSRO) Plans to Launch Niraparib in U.S in 1H 2017 for Ovarian Cancer
Ticker: TSRO
Occurred on: Apr 19, 2017 -
Tesaro (TSRO) Plans Commercial Launch By Year End in Europe for Niraparib in Treatment of Ovarian Cancer
Ticker: TSRO
Occurred on: Apr 19, 2017 -
Tesaro (TSRO) Plans to Finalize Potential Lung Cancer Registration Study and Initiate Development Program for Niraparib in 1H 2017
Ticker: TSRO
Occurred on: Mar 27, 2017 -
Tesaro (TSRO) Plans to Report Phase 3 BRAVO Data in 2H 2017 Evaluating Niraparib in BRCA Positive Breast Cancer
Ticker: TSRO
Occurred on: Mar 27, 2017 -
Tesaro's (TSRO) Rolapitant IV Rejected by FDA for the Prevention of Delayed Nausea and Vomiting Associated with Emetogenic Chemotherapy
Ticker: TSRO
Occurred on: Jan 12, 2017 -
Tesaro (TSRO) Presents Phase 3 ENGOT-OV16/NOVA Data Evaluating Niraparib in Ovarian Cancer Regardless of BRCA Status
Ticker: TSRO
Occurred on: Oct 10, 2016 -
Tesaro (TSRO) planning for NDA and MAA submissions for Niraparib in the second half of this year
Ticker: TSRO
Occurred on: Sep 12, 2016 -
TESARO's Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial
Tickers: TSRO, CLVS
Occurred on: Jun 29, 2016 -
Tesaro (TSRO) expects Phase 2 data from QUADRA study of Niraparib in subjects with ovarian cancer in Q2 2016
Ticker: TSRO
Occurred on: Jun 29, 2016 -
Tesaro (TSRO) anticipates data from Phase 3 NOVA trial of Niraparib in patients with ovarian cancer in Q2 2016
Ticker: TSRO
Occurred on: Jun 29, 2016 -
Tesaro (TSRO) plans to submit IND for TSR-022 (anti-TIM-3 antibody candidate) in Q2 2016
Ticker: TSRO
Occurred on: Apr 25, 2016 -
Tesaro (TSRO) to submit the MAA for oral rolapitant to the EMA in Q2 2016
Ticker: TSRO
Occurred on: Mar 23, 2016 -
Tesaro (TSRO) completes 150MM private placement at $35.19 per share
Ticker: TSRO
Occurred on: Mar 18, 2016 -
Tesaro (TSRO) has submitted New Drug Application (NDA) for an intravenous (IV) formulation of rolapitant to the FDA
Ticker: TSRO
Occurred on: Mar 14, 2016 -
TESARO (TSRO) Presents Three Posters on Niraparib at the 2015 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
Ticker: TSRO
Occurred on: Nov 09, 2015 -
Tesaro (TSRO) to finish Phase 1/2 study of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas in July 2016
Ticker: TSRO
Occurred on: Oct 29, 2015 -
Tesaro (TSRO) recieves FDA approval of VARUBI, an NK1 receptor antagonist for the prevention of CINV
Ticker: TSRO
Occurred on: Sep 01, 2015
Strategic Initiatives (TSRO)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
